Abstract
This prospective study analyzed oncologic and functional results of transoral robotic surgery (TORS) and ascertained the validity of TORS as a minimally invasive therapy for oropharyngeal cancer. Between April 2008 and September 2011, 39 patients with oropharyngeal cancer underwent TORS. The Kaplan–Meier method was used to analyze overall and disease-free survival rate. Videopharyngogram study (VEF) and the functional outcome swallowing scale (FOSS) were used to evaluate swallowing function. Nasometer study was conducted to estimate hypernasality, and acoustic waveform analysis was used to evaluate voice status. A negative margin was reported in 94.9% of patients. Overall survival at two years was 96% and disease-free survival was 92%. An oral diet was tolerable after an average of 6.4 days. Significant swallowing difficulties were not observed for the VEF results. Favorable swallowing results were found in 97.4% of patients with FOSS scores ranging from 0 to 2. Voice parameters were maintained close to the normal range on the acoustic waveform analysis. The oncologic and functional results of TORS were quite acceptable for the treatment of oropharyngeal cancer. TORS is a valid treatment option for select patients with oropharyngeal cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
